88 related articles for article (PubMed ID: 23807540)
1. Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions.
Kriška J; Solár P; Varinská L; Solárová Z; Kimáková P; Mojžiš J; Fedoročko P; Sytkowski AJ
Oncol Rep; 2013 Sep; 30(3):1455-62. PubMed ID: 23807540
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype.
Solar P; Feldman L; Jeong JY; Busingye JR; Sytkowski AJ
Int J Cancer; 2008 Jan; 122(2):281-8. PubMed ID: 17893875
[TBL] [Abstract][Full Text] [Related]
4. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells.
Paragh G; Kumar SM; Rakosy Z; Choi SC; Xu X; Acs G
Am J Pathol; 2009 Apr; 174(4):1504-14. PubMed ID: 19264915
[TBL] [Abstract][Full Text] [Related]
5. The long noncoding RNA MALAT1 promotes tumor-driven angiogenesis by up-regulating pro-angiogenic gene expression.
Tee AE; Liu B; Song R; Li J; Pasquier E; Cheung BB; Jiang C; Marshall GM; Haber M; Norris MD; Fletcher JI; Dinger ME; Liu T
Oncotarget; 2016 Feb; 7(8):8663-75. PubMed ID: 26848616
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
7. Location and the functionality of erythropoietin receptor(s) in A2780 cells.
Solár P; Hrčková G; Varinská L; Solárová Z; Kriška J; Uhrínová I; Kello M; Mojžiš J; Fedoročko P; Sytkowski AJ
Oncol Rep; 2012 Jul; 28(1):141-6. PubMed ID: 22552716
[TBL] [Abstract][Full Text] [Related]
8. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin-dependent suppression of the expression of the beta subunits of the interleukin-3 receptor during erythroid differentiation.
Carta C; Campisi S; Migliaccio G; Migliaccio AR
Blood Cells Mol Dis; 2000 Oct; 26(5):467-78. PubMed ID: 11112384
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells.
Solár P; Koval J; Mikes J; Kleban J; Solárová Z; Lazúr J; Hodorová I; Fedorocko P; Sytkowski AJ
Mol Cancer Ther; 2008 Aug; 7(8):2263-71. PubMed ID: 18687658
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells.
Zwezdaryk KJ; Coffelt SB; Figueroa YG; Liu J; Phinney DG; LaMarca HL; Florez L; Morris CB; Hoyle GW; Scandurro AB
Exp Hematol; 2007 Apr; 35(4):640-52. PubMed ID: 17379074
[TBL] [Abstract][Full Text] [Related]
12. Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role of hypoxia in tumorigenesis.
Gombos Z; Danihel L; Repiska V; Acs G; Furth E
Indian J Pathol Microbiol; 2011; 54(2):273-8. PubMed ID: 21623073
[TBL] [Abstract][Full Text] [Related]
13. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.
Jeong JY; Feldman L; Solar P; Szenajch J; Sytkowski AJ
Int J Cancer; 2008 Jan; 122(2):274-80. PubMed ID: 17893874
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells.
Hale SA; Wong C; Lounsbury KM
Gynecol Oncol; 2006 Jan; 100(1):14-9. PubMed ID: 16226302
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
16. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells.
Lopez TV; Lappin TR; Maxwell P; Shi Z; Lopez-Marure R; Aguilar C; Rocha-Zavaleta L
Int J Cancer; 2011 Dec; 129(11):2566-76. PubMed ID: 21442620
[TBL] [Abstract][Full Text] [Related]
17. Modulation of intestinal folate absorption by erythropoietin in vitro.
Yan J; Jin G; Du L; Yang Q
Mol Pharm; 2014 Jan; 11(1):358-66. PubMed ID: 24294939
[TBL] [Abstract][Full Text] [Related]
18. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition.
Gabellini C; De Luca T; Trisciuoglio D; Desideri M; Di Martile M; Passeri D; Candiloro A; Biffoni M; Rizzo MG; Orlandi A; Del Bufalo D
Carcinogenesis; 2013 Nov; 34(11):2558-67. PubMed ID: 23836782
[TBL] [Abstract][Full Text] [Related]
19. Inducible nitric oxide synthase expression and erythropoietin production in human hepatocellular carcinoma cells.
Yoshioka K; Thompson J; Miller MJ; Fisher JW
Biochem Biophys Res Commun; 1997 Mar; 232(3):702-6. PubMed ID: 9126339
[TBL] [Abstract][Full Text] [Related]
20. Lack of functional erythropoietin receptors of cancer cell lines.
Laugsch M; Metzen E; Svensson T; Depping R; Jelkmann W
Int J Cancer; 2008 Mar; 122(5):1005-11. PubMed ID: 17990315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
